BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 29340082)

  • 1. Reciprocal sensitivity of diffuse large B-cell lymphoma cells to Bcl-2 inhibitors BIRD-2 versus venetoclax.
    Vervloessem T; Akl H; Tousseyn T; De Smedt H; Parys JB; Bultynck G
    Oncotarget; 2017 Dec; 8(67):111656-111671. PubMed ID: 29340082
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A dual role for the anti-apoptotic Bcl-2 protein in cancer: mitochondria versus endoplasmic reticulum.
    Akl H; Vervloessem T; Kiviluoto S; Bittremieux M; Parys JB; De Smedt H; Bultynck G
    Biochim Biophys Acta; 2014 Oct; 1843(10):2240-52. PubMed ID: 24768714
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HA14-1 potentiates apoptosis in B-cell cancer cells sensitive to a peptide disrupting IP 3 receptor / Bcl-2 complexes.
    Akl H; La Rovere RM; Janssens A; Vandenberghe P; Parys JB; Bultynck G
    Int J Dev Biol; 2015; 59(7-9):391-8. PubMed ID: 26260683
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Constitutive IP
    Bittremieux M; La Rovere RM; Akl H; Martines C; Welkenhuyzen K; Dubron K; Baes M; Janssens A; Vandenberghe P; Laurenti L; Rietdorf K; Morciano G; Pinton P; Mikoshiba K; Bootman MD; Efremov DG; De Smedt H; Parys JB; Bultynck G
    Cell Death Differ; 2019 Mar; 26(3):531-547. PubMed ID: 29899382
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BIRD-2, a BH4-domain-targeting peptide of Bcl-2, provokes Bax/Bak-independent cell death in B-cell cancers through mitochondrial Ca
    Kerkhofs M; La Rovere R; Welkenhuysen K; Janssens A; Vandenberghe P; Madesh M; Parys JB; Bultynck G
    Cell Calcium; 2021 Mar; 94():102333. PubMed ID: 33450506
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A synthetic peptide targeting the BH4 domain of Bcl-2 induces apoptosis in multiple myeloma and follicular lymphoma cells alone or in combination with agents targeting the BH3-binding pocket of Bcl-2.
    Lavik AR; Zhong F; Chang MJ; Greenberg E; Choudhary Y; Smith MR; McColl KS; Pink J; Reu FJ; Matsuyama S; Distelhorst CW
    Oncotarget; 2015 Sep; 6(29):27388-402. PubMed ID: 26317541
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting Bcl-2-IP
    Distelhorst CW
    Biochim Biophys Acta Mol Cell Res; 2018 Nov; 1865(11 Pt B):1795-1804. PubMed ID: 30053503
    [TBL] [Abstract][Full Text] [Related]  

  • 8. IP3R2 levels dictate the apoptotic sensitivity of diffuse large B-cell lymphoma cells to an IP3R-derived peptide targeting the BH4 domain of Bcl-2.
    Akl H; Monaco G; La Rovere R; Welkenhuyzen K; Kiviluoto S; Vervliet T; Molgó J; Distelhorst CW; Missiaen L; Mikoshiba K; Parys JB; De Smedt H; Bultynck G
    Cell Death Dis; 2013 May; 4(5):e632. PubMed ID: 23681227
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The selective Bcl-2 inhibitor venetoclax, a BH3 mimetic, does not dysregulate intracellular Ca
    Vervloessem T; Ivanova H; Luyten T; Parys JB; Bultynck G
    Biochim Biophys Acta Mol Cell Res; 2017 Jun; 1864(6):968-976. PubMed ID: 27913204
    [TBL] [Abstract][Full Text] [Related]  

  • 10. DLBCL Cells with Acquired Resistance to Venetoclax Are Not Sensitized to BIRD-2 But Can Be Resensitized to Venetoclax through Bcl-XL Inhibition.
    Kerkhofs M; Vervloessem T; Stopa KB; Smith VM; Vogler M; Bultynck G
    Biomolecules; 2020 Jul; 10(7):. PubMed ID: 32708132
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Extracellular and ER-stored Ca
    Bittremieux M; La Rovere RM; Schuermans M; Luyten T; Mikoshiba K; Vangheluwe P; Parys JB; Bultynck G
    Cell Death Discov; 2018; 4():101. PubMed ID: 30416758
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Allosteric cross-talk between the hydrophobic cleft and the BH4 domain of Bcl-2 in control of inositol 1,4,5-trisphosphate receptor activity.
    Shapovalov G; Ritaine A; Essonghe NC; de Ridder I; Ivanova H; Karamanou S; Economou A; Bultynck G; Skryma R; Prevarskaya N
    Explor Target Antitumor Ther; 2022; 3(3):375-391. PubMed ID: 36045908
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The selective BH4-domain biology of Bcl-2-family members: IP3Rs and beyond.
    Monaco G; Vervliet T; Akl H; Bultynck G
    Cell Mol Life Sci; 2013 Apr; 70(7):1171-83. PubMed ID: 22955373
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cancer cell death strategies by targeting Bcl-2's BH4 domain.
    de Ridder I; Kerkhofs M; Veettil SP; Dehaen W; Bultynck G
    Biochim Biophys Acta Mol Cell Res; 2021 Apr; 1868(5):118983. PubMed ID: 33549704
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regulation of the ryanodine receptor by anti-apoptotic Bcl-2 is independent of its BH3-domain-binding properties.
    Vervliet T; Lemmens I; Welkenhuyzen K; Tavernier J; Parys JB; Bultynck G
    Biochem Biophys Res Commun; 2015 Jul; 463(3):174-9. PubMed ID: 25957473
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BDA-366, a putative Bcl-2 BH4 domain antagonist, induces apoptosis independently of Bcl-2 in a variety of cancer cell models.
    Vervloessem T; Sasi BK; Xerxa E; Karamanou S; Kale J; La Rovere RM; Chakraborty S; Sneyers F; Vogler M; Economou A; Laurenti L; Andrews DW; Efremov DG; Bultynck G
    Cell Death Dis; 2020 Sep; 11(9):769. PubMed ID: 32943617
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acquired resistance to venetoclax (ABT-199) in t(14;18) positive lymphoma cells.
    Bodo J; Zhao X; Durkin L; Souers AJ; Phillips DC; Smith MR; Hsi ED
    Oncotarget; 2016 Oct; 7(43):70000-70010. PubMed ID: 27661108
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A double point mutation at residues Ile14 and Val15 of Bcl-2 uncovers a role for the BH4 domain in both protein stability and function.
    Monaco G; La Rovere R; Karamanou S; Welkenhuyzen K; Ivanova H; Vandermarliere E; Di Martile M; Del Bufalo D; De Smedt H; Parys JB; Economou A; Bultynck G
    FEBS J; 2018 Jan; 285(1):127-145. PubMed ID: 29131545
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bcl-2 inhibitors as anti-cancer therapeutics: The impact of and on calcium signaling.
    Vervloessem T; Kerkhofs M; La Rovere RM; Sneyers F; Parys JB; Bultynck G
    Cell Calcium; 2018 Mar; 70():102-116. PubMed ID: 28705421
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synergistic killing of human small cell lung cancer cells by the Bcl-2-inositol 1,4,5-trisphosphate receptor disruptor BIRD-2 and the BH3-mimetic ABT-263.
    Greenberg EF; McColl KS; Zhong F; Wildey G; Dowlati A; Distelhorst CW
    Cell Death Dis; 2015 Dec; 6(12):e2034. PubMed ID: 26720343
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.